What is it about?
Obstructive sleep apnea is common in patients with coronary artery disease, many of whom do not report daytime sleepiness. Continuous positive airway pressure is first-line treatment for symptomatic obstructive sleep apnea, but its value in patients without daytime sleepiness is uncertain.
Featured Image
Why is it important?
This is the first randomized controlled study to address impact of continuous positive airway pressure on adverse cardiovascular outcomes in revascularized coronary artery disease patients with obstructive sleep apnea but no daytime sleepiness. Routine prescription of the device did not reduce the adverse outcomes in this high-risk population in intention-to-treat analysis. However, there was a significant reduction after adjustment for baseline comorbidities and compliance with treatment.
Perspectives
Adherence to treatment is crucial in such kind of randomized controlled trials. These findings need to be further explored in larger clinical cohorts with more homogenous cardiac populations.
Prof. Dr Yuksel Peker
Read the Original
This page is a summary of: Effect of Positive Airway Pressure on Cardiovascular Outcomes in Coronary Artery Disease Patients with Nonsleepy Obstructive Sleep Apnea. The RICCADSA Randomized Controlled Trial, American Review of Respiratory Disease, September 2016, American Thoracic Society,
DOI: 10.1164/rccm.201601-0088oc.
You can read the full text:
Contributors
The following have contributed to this page
